๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced Lung Neuroendocrine Tumor

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites๐Ÿ“ Beijing๐Ÿ“ Zhengzhou๐Ÿ“ Hangzhou Beijing Tide Pharmaceutical Co., Ltd ยท Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Columbus Tanabe Pharma America, Inc. ยท Tests: MT-4561 A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site๐Ÿ“ Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. ยท Tests: Autologous tumor infiltrating lymphocytes (TILs) Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site๐Ÿ“ Jinan Mainline Biosciences (Shanghai) Co., Ltd ยท Tests: MB0151 for injection Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Shanghai GV20 Therapeutics ยท Tests: GV20-0251 Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. NCT06440057Phase 1, Phase 21 site๐Ÿ“ Beijing Suzhou Zelgen Biopharmaceuticals Co.,Ltd ยท Tests: ZG006 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites๐Ÿ“ Clovis๐Ÿ“ Los Angeles๐Ÿ“ Newport Beach Bristol-Myers Squibb ยท Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites๐Ÿ“ Aurora๐Ÿ“ Lake Mary๐Ÿ“ Lebanon 7 Hills Pharma, LLC ยท Tests: Alintegimod, Ipilimumab, Nivolumab Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC NCT07718243Phase 1, Phase 22 sites๐Ÿ“ Manchester๐Ÿ“ Sutton Institute of Cancer Research, United Kingdom ยท Tests: Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors NCT06942143Phase 11 site๐Ÿ“ Guangzhou Guangzhou FineImmune Biotechnology Co., LTD. ยท Tests: Super1 TCR-T A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites๐Ÿ“ Grand Rapids๐Ÿ“ St Louis๐Ÿ“ Pittsburgh AstraZeneca ยท Tests: AZD6750, rilvegostomig Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) NCT07016230Phase 23 sites๐Ÿ“ Bordeaux๐Ÿ“ Nice๐Ÿ“ Villejuif Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: Tarlatamab VSV-02 Compassionate Use in Advanced Solid Tumors NCT07260591Phase 11 site๐Ÿ“ Xinxiang The First Affiliated Hospital of Xinxiang Medical College ยท Tests: VSV-02 Injection FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum NCT06393816Phase 231 sites๐Ÿ“ Aix-en-Provence๐Ÿ“ Amiens๐Ÿ“ Angers Centre Leon Berard ยท Tests: Durvalumab with etoposide and Carboplatin/Cisplatin EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ยฑ Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EBNK-001 + IL-15 + Pembrolizumab A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ New Haven GV20 Therapeutics ยท Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDAยฎ], GV20-0251 and Pembrolizumab [KEYTRUDAยฎ] Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites๐Ÿ“ Iowa City๐Ÿ“ Boston๐Ÿ“ Royal Oak Novartis Pharmaceuticals ยท Tests: 225Ac-ETN029, 111In-ETN029 A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites๐Ÿ“ Phoenix๐Ÿ“ San Francisco๐Ÿ“ Hartford BioNTech SE ยท Tests: BNT326, Pumitamig, Itraconazole, Paroxetine A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937Phase 15 sites๐Ÿ“ Beijing๐Ÿ“ Changsha๐Ÿ“ Nanchang Hangzhou DAC Biotechnology Co., Ltd. ยท Tests: DXC014 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites๐Ÿ“ Scottsdale๐Ÿ“ Bethesda๐Ÿ“ Columbus Novartis Pharmaceuticals ยท Tests: dabrafenib, trametinib MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760Phase 12 sites๐Ÿ“ Tampa๐Ÿ“ Durham Memgen, Inc. ยท Tests: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel BostonGene and Exigent Genomic INsight Study NCT06272864n/a7 sites๐Ÿ“ Rogers๐Ÿ“ Stockton๐Ÿ“ Fort Wayne BostonGene Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab NCT07751042Phase 1, Phase 24 sites๐Ÿ“ Scottsdale๐Ÿ“ Boston๐Ÿ“ Nashville Strand Therapeutics Inc. ยท Tests: STX-003, KEYTRUDAยฎ Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer NCT06283719Phase 1, Phase 21 site๐Ÿ“ Shanghai Suzhou Zelgen Biopharmaceuticals Co.,Ltd ยท Tests: ZG006 Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors NCT04665739Phase 229 sites๐Ÿ“ Birmingham๐Ÿ“ Beverly Hills๐Ÿ“ Loma Linda National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680Phase 258 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Atlanta Bristol-Myers Squibb ยท Tests: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116Phase 1, Phase 2165 sites๐Ÿ“ Duarte๐Ÿ“ Glendale๐Ÿ“ La Jolla Turning Point Therapeutics, Inc. ยท Tests: Oral repotrectinib (TPX-0005) Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors NCT06596915Phase 11 site๐Ÿ“ Beijing Shandong Boan Biotechnology Co., Ltd ยท Tests: BA1302
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy